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Abstract
Integrins are cell adhesion molecules that mediate cell-cell, cell-extracellular matrix, and cell-
pathogen interactions. They play critical roles for the immune system in leukocyte trafficking and
migration, immunological synapse formation, costimulation, and phagocytosis. Integrin
adhesiveness can be dynamically regulated through a process termed inside-out signaling. In
addition, ligand binding transduces signals from the extracellular domain to the cytoplasm in the
classical outside-in direction. Recent structural, biochemical, and biophysical studies have greatly
advanced our understanding of the mechanisms of integrin bidirectional signaling across the plasma
membrane. Large-scale reorientations of the ectodomain of up to 200 Å couple to conformational
change in ligand-binding sites and are linked to changes in α and β subunit transmembrane domain
association. In this review, we focus on integrin structure as it relates to affinity modulation, ligand
binding, outside-in signaling, and cell surface distribution dynamics.
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Introduction
The immune system relies heavily on integrins for (a) adhesion during leukocyte trafficking
from the bloodstream, migration within tissues, immune synapse formation, and phagocytosis;
and (b) signaling during costimulation and cell polarization. Integrins are so named because
they integrate the extracellular and intracellular environments by binding to ligands outside
the cell and cytoskeletal components and signaling molecules inside the cell. Integrins are
noncovalently associated heterodimeric cell surface adhesion molecules. In vertebrates, 18 α
subunits and 8 β subunits form 24 known αβ pairs (Figure 1). This diversity in subunit
composition contributes to diversity in ligand recognition, binding to cytoskeletal components
and coupling to downstream signaling pathways. Immune cells express at least 10 members
of the integrin family belonging to the β2, β7, and β1 subfamilies (Table 1). The β2 and β7
integrins are exclusively expressed on leukocytes, whereas the β1 integrins are expressed on
a wide variety of cells throughout the body. Distribution and ligand-binding properties of the
integrins on leukocytes are summarized in Table 1. For reviews, see References 1 and 2.
Mutations that block expression of the β2 integrin subfamily lead to leukocyte adhesion
deficiency, a disease associated with severe immunodeficiency (3).
As adhesion molecules, integrins are unique in that their adhesiveness can be dynamically
regulated through a process termed inside-out signaling or priming. Thus, stimuli received by
cell surface receptors for chemokines, cytokines, and foreign antigens initiate intracellular
signals that impinge on integrin cytoplasmic domains and alter adhesiveness for extracellular
ligands. In addition, ligand binding transduces signals from the extracellular domain to the
cytoplasm in the classical outside-in direction (outside-in signaling). These dynamic properties
of integrins are central to their proper function in the immune system. Indeed, mutations or
small molecules that stabilize either the inactive state or the active adhesive state—and thereby
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block the adhesive dynamics of leukocyte integrins—inhibit leukocyte migration and normal
immune responses.
Integrin α I Domains
Half of integrin α subunits contain a domain of about 200 amino acids known as an inserted
(I) domain, or a von Willebrand factor A domain (Figure 1). In integrins in which it is present,
the α I domain is the major or exclusive ligand-binding site. In this review, we begin with the
α I domain because it serves as a paradigm for understanding conformational regulation and
ligand binding for all integrins. Subsequently, we describe the complex ectodomain
architecture shared by all integrins, including 12 different domains, one of which in the β
subunit is homologous to the α I domain.
α I Domain Structure
The α I domain can be expressed independently of other integrin domains and was the first
domain to be crystallized (4). Several structures of α I domains bound to ligands are now
available, including the α2 I domain bound to a triple-helical collagen peptide (5) and αL I
domains with mutationally introduced disulfide bonds bound to intercellular adhesion
molecule (ICAM)-1 and ICAM-3 (6,7) (Figure 2). The α I domain adopts the dinucleotide-
binding or Rossmann fold, with α-helices surrounding a central β-sheet (Figure 2). β-strands
and α-helices tend to alternate in the secondary structure, with the α-helices wrapping around
the domain in counterclockwise order when viewed from the “top” face. A divalent cation-
binding site, which physiologically binds Mg2+, defines the top face of the domain. The bound
Mg2+ is ligated by five side chains located in three different loops (Figure 3). The first of these
loops, between β-strand 1 and α-helix 1, i.e., the β1-α1 loop, contains three coordinating
residues in a sequence that is a signature of I domains, Asp-Xaa-Ser-Xaa-Ser or DXSXS. The
second loop donates a coordinating Thr residue, and the third loop donates an Asp. Divalent
cations are universally required for ligand binding by integrins, and in α I domains the metal-
coordinating residues, and the residues surrounding the metal-binding site, are important for
ligand binding. Therefore, this site has been designated the metal ion-dependent adhesion site
(MIDAS).
Conformational Regulation of α I Domains
Structural studies of α I domains in the presence and absence of ligand, and with mutations
that stabilize distinct affinity states, have provided a mechanistic understanding of
conformational regulation during both priming and ligand binding. I domains have been
crystallized in three distinct conformations, termed closed, intermediate, and open (4–6,8).
These demonstrate distinct coordination of the metal in the MIDAS, arrangement of the β6-
α7 loop, and axial disposition of the C-terminal α7-helix along the side of the I domain (5,6,
8) (Figure 4a). At the α I domain MIDAS, five residues and several water molecules contribute
oxygen atoms to the primary and secondary coordination spheres surrounding the metal (Figure
3). In the open conformation of the MIDAS, two serines and one threonine are in the primary
coordination sphere, whereas two aspartic acid residues are in the secondary coordination
sphere (Figure 3b). Notably, the glutamic acid residue, which is contributed by the ligand or
ligand-mimetic lattice contact, donates the only negatively charged oxygen to the primary
coordination sphere in the open conformation (E314 in Figure 3b). The lack of any charged
group in the primary coordination sphere donated by the I domain is hypothesized to enhance
the strength of the metal-ligand bond. In the closed conformation of the α I domain (Figure
3a), the threonine moves from the primary to the secondary coordination sphere, and one of
the aspartic acid residues moves from the secondary to the primary coordination sphere. The
backbone and side chain rearrangements in the α I domain are accompanied by a 2.3 Å
“sideways” movement of the metal ion away from the threonine and toward the aspartic acid
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on the opposite side of the coordination shell. The closed and open structures are consistent
with the idea that an energetically favorable MIDAS requires at least one primary coordination
to a negatively charged oxygen. In the absence of a ligand, pseudoligand, and the remainder
of the integrin ectodomain, wild-type α I domains crystallize in the closed conformation. The
closed conformation therefore appears to be the low-energy conformation, as verified
computationally (9). However, with an engineered disulfide bond that was designed to stabilize
the open conformation, an αL I domain crystallized in the open conformation in the absence
of a ligand-mimetic lattice contact (6). This demonstrates that, in principle, interactions with
other integrin domains might be capable of stabilizing an unliganded I domain in the open
conformation and activating or priming it for ligand binding.
Change in coordination at the MIDAS of α I domains is coupled to backbone movements of
loops that bear the coordinating residues. Several of these loops, including the β1-α1 and β4-
α5 loops, also bear residues that directly contact ligand, and thus their movement increases
complementarity to ligand. To accommodate these rearrangements, the β6-α7 loop undergoes
the largest shift of all, although it is not a MIDAS loop nor does it contact ligand. Coupled to
the β6-α7 loop rearrangement, the C-terminal α7-helix moves 7 Å down the side of the domain
(Figure 4a). The axial displacement of the α7-helix represents the critical linkage for
transmission of conformational signals between the MIDAS of the α I domain and other integrin
domains, as discussed below. Engineered disulfide bonds that stabilize the α7-helix in
intermediate and open conformations (shifted axially downward by approximately 3 Å or 7 Å
relative to the closed conformation, respectively) induced rearrangements in the MIDAS and
surrounding loops that were coupled to 500- and 10,000-fold increases in affinity for ICAM-1,
respectively (6). As mentioned above, the downward movement of the α7-helix is sufficient
for priming the α I domain into higher-affinity states. Crystal structures have been obtained of
intermediate- and high-affinity mutant αL I domains both in the absence and presence of ligands
(6,7). For example, Figure 2 shows a complex between ICAM-3 and a high-affinity αL I domain
mutant with a disulfide bond introduced into the β6-α7 loop to stabilize the open conformation.
Conversely, binding of wild-type I domains to ligand at the extremely high, ∼mM,
concentrations used in crystallization can induce MIDAS rearrangements and downward
displacement of the α7-helix (5). Thus, the transmission of inside-out and outside-in signaling
within the I domain occurs along the same pathway but flows in opposite directions.
The ability to modulate affinity by 10,000-fold demonstrates the exquisite efficiency of the α
I domain in coupling change in conformation to change in affinity. Remarkably, through
directed evolution an engineered αL I domain mutant (F265S/F292G) was recently obtained
with an increase of 200,000-fold in affinity for ICAM-1 (10). However, whether α I domains
achieve such high affinities for ligands under physiological conditions is unknown. A high-
affinity state of integrins on intact cells can be induced by addition of Mn2+, which, as reviewed
below, increases integrin affinity by replacing Ca2+ at the ADMIDAS site of the β I domain.
Interestingly, activation of integrin adhesiveness on intact cells by physiologic stimuli appears
to result in lower affinity than that induced by Mn2+. Therefore, investigators have
hypothesized that an intermediate conformational state with intermediate affinity for ligand is
important for physiologic, fine-tuned regulation of αLβ2 adhesiveness (11). Molecular
dynamic studies showed that the intermediate conformation of the α I domain is on the pathway
from the closed to the open conformation of the αL and αM I domains (12).
A monoclonal antibody (mAb), AL-57, has been developed by phage display that selectively
targets the high-affinity open conformation of the αL I domain (13,14). AL-57 does not bind
the low-affinity state of leukocyte function-associated antigen (LFA)-1 (αLβ2) but does bind
the intermediate- and high-affinity states of the αL I domain with KD of 4.7 μM and 23 nM,
respectively. AL-57 is ligand-mimetic because it binds only upon activation and requires
Mg2+ for binding. Interestingly, monovalent Fab AL-57 demonstrates affinity increases on a
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subset (∼10%) of lymphocyte cell surface LFA-1 molecules upon stimulation with chemokine
CXCL-12 and PMA (phorbol 12-myristate 13-acetate). These results are consistent with
previous observations on Mac-1 on neutrophils (15) and suggest that after physiologic
activation a subset of cell surface Mac-1 molecules on neutrophils and LFA-1 molecules on
lymphocytes are converted to a higher-affinity state. This active subset of molecules mediates
adhesion because the antibodies specific for this subset of 10% to 30% of surface molecules
completely inhibit cell adhesion.
Allosteric α I Domain Inhibitors
Small molecule allosteric inhibitors provide further support for the role of the α7-helix in α I
domain regulation. One class of small molecule inhibitors, termed α I allosteric antagonists,
binds underneath the C-terminal α-helix of the αL I domain (16–18). Such antagonists stabilize
the closed conformation of the I domain by preventing downward axial shift of the α7-helix
and thereby preventing MIDAS rearrangements necessary for efficient ligand binding. The
mode of action of these antagonists is confirmed by the finding that a mutant αL I domain that
stabilizes the high-affinity, open conformation of the C-terminal α7-helix with an engineered
disulfide bond is resistant to inhibition by α I allosteric antagonists (11,19,20).
Ligand Recognition by α I Domains
Ligand recognition by α I domains has been elucidated by crystal structures of the α2 I domain
in complex with a triple-helical collagenous peptide (5) and the αL I domain in complex with
ICAM-1 and ICAM-3 (6,7). ICAM-1, -2, -3, -4, and -5 are cell surface molecules with 2 to 9
IgSF domains (Figure 5). They share much more sequence identity with one another (30% to
50%) than with other IgSF molecules and thus comprise a subfamily of the Ig superfamily.
Except for ICAM-4, they all bind to αLβ2 through a key glutamic acidic residue in domain 1
(21). The order of binding affinities for αLβ2 is ICAM-1 > ICAM-2 > ICAM-3 (11). In the
structure of the αL I domain bound to ICAM-1 (6) or ICAM-3 (7), Glu-34 (ICAM-1) or Glu-37
(ICAM-3) at the end of the β-strand C of domain 1 forms a direct coordination to the Mg2+ in
the α I domain MIDAS (Figure 2). This metal-coordination bond is surrounded by a ring of
hydrophobic residues in both the α I domain and ICAM-1. The surrounding nonpolar
environment strengthens the Coulombic interaction between the Glu and Mg2+. Surrounding
the hydrophobic ring are polar interactions involving hydrogen bonds and salt bridges. The
nonpolar region in ICAM-1 is more polar in ICAM-3 and appears to account for the lower
affinity of αLβ2 for ICAM-3 than for ICAM-1 (7). In support of this finding, increasing the
hydrophobicity of the nonpolar ring even further in ICAM-1 by structure-guided mutagenesis
increases the affinity of αLβ2 for ICAM-1 (22). ICAM-1 and ICAM-3 dock in the same
orientation to the αL I domain, and the structure of ICAM-2 (23) suggests an essentially
identical docking mechanism.
The structure of the αL I domain bound to a portion of ICAM-1 (6) combined with a
complementary structure containing the remaining portion of ICAM-1 (24) have provided a
topological view of the αLβ2-ICAM-1 interaction as it might take place during cell-cell
interactions (Figure 5b). αLβ2- and αMβ2-binding sites on ICAM-1 are located on D1 and D3,
respectively. ICAM-1 exists on the cell surface predominantly as a homodimer (25,26).
Relatively strong but reversible dimerization takes place in D4 by merging of the β-sheets of
two D4 domains into β-supersheets, as revealed by an ICAM-1 D3-D5 crystal structure (24).
An apparently weaker hydrophobic dimerization interface in D1 has been revealed in different
crystal structures, including the ICAM-1 D1-D2 complex with the αL I domain (6). Together,
the αL I domain-ICAM-1 D1-D2 and the ICAM-1 D3-D5 structures show that ICAM-1 dimers
are Y-shaped and that the dimeric interface at D4 and D5 provides a rigid stem to orient D1-
D3 optimally for binding integrins on opposing cell surfaces (24) (Figure 5a). Furthermore,
dimerization at D1 could link neighboring Y-shaped dimers yielding a one-dimensional array
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of ICAM-1 molecules on the cell surface (Figure 5b), which has an architecture appropriate
for displaying the αLβ2-binding site in D1 and the αMβ2-binding site in D3 for recognition by
integrins on an opposing cell (24).
In contrast to αLβ2, the αMβ2 and αXβ2 integrins bind to a range of diverse ligands, including
ICAMs, fibrinogen, iC3b, heparin, and denatured and proteolyzed proteins (27–29).
Proteolysis and denaturation enhance binding of αM and especially of αX I domains to
fibrinogen, and investigators have proposed that αXβ2 functions as a danger receptor for
proteolyzed and denatured proteins (29). In marked contrast to αL, the αX and αM I domains
show a KD for small molecules with carboxyl groups of ∼100 μM. This relaxed ligand
specificity is consistent with the ability of the wild-type αM I domain to engage in ligand-
mimetic lattice contacts in crystals. In these contacts, the MIDAS binds to a glutamic acid
residue in a neighboring αM I domain in the crystal lattice (Figure 3b), and the I domain
crystallizes in the open conformation (4).
Integrin Global Topology
A complete understanding of integrin regulation requires knowledge of how conformational
information is transmitted through the many domains that link the ligand-binding domains to
the transmembrane and cytoplasmic domains. Both the integrin α and β subunits are type I
transmembrane glycoproteins with large extracellular domains, single-spanning
transmembrane domains, and, with the exception of β4, short cytoplasmic domains (Figure
6a,b). From electron microscopy (EM), investigators have known for years that the overall
topology of integrins included an extracellular, globular, N-terminal ligand-binding head
domain, representing a critical α and β subunit interface, standing on two long and extended
C-terminal legs or stalks, which connect to the transmembrane and cytoplasmic domains of
each subunit (30). However, X-ray crystal structures of the extracellular domain of the integrin
αVβ3 provided the surprising finding that the legs were severely bent, generating a V-shaped
topology in which the head domain was closely juxtaposed to the membrane-proximal portions
of the legs (31,32) (Figure 6c and Figure 7a). Since the elucidation of these initial structures,
an increasing number of studies have together established that the bent conformation represents
the physiological low-affinity state, whereas priming and ligand binding are associated with a
large-scale global conformational rearrangement in which the integrin extends with a
switchblade-like motion (33–36) (Figure 6c,d). The most recent studies have elucidated the
detailed mechanisms for linking these global rearrangements to intradomain conformational
changes that are associated with affinity modulation and ligand binding.
The Ligand-Binding Head
The N-terminal region of the integrin α subunit contains seven segments of about 60 amino
acids, each with weak sequence similarity to one another. These were initially predicted (37)
and later confirmed by crystal structures (31,36) to fold into a seven-bladed β-propeller domain.
When present, the α I domain is inserted between β-sheets 2 and 3 of the β-propeller (Figure
6a,b). An inserted domain in the β subunit, the β I domain, is homologous to the α I domain,
except that it contains two additional segments; one of these helps form the interface with the
β-propeller and the other is known as the specificity-determining loop (SDL) because of its
role in ligand binding (Figure 6a,b and Figure 7c). One side of the β I domain binds to the
upper hub of the β-propeller domain directly over the pseudosymmetry axis of the β-propeller
(Figure 7c). The extensive interface, which buries 1700 Å2 of solvent-accessible surface area
on each side, is much greater than any other domain-domain interface in integrins, including
interfaces between domains that are contiguous in sequence in the α and β subunits. Mutations
in the β2 I domain that disrupt this interface cause leukocyte adhesion deficiency (38,39). The
opposite, lower face of the α subunit β-propeller domain is stabilized by Ca2+ ions that bind
to Ca2+-binding β-hairpin motifs (Figure 7b,c). Like the α I domain, the β I domain contains
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a MIDAS for binding negatively charged residues, which physiologically binds Mg2+ (36).
Additionally, there are two adjacent metal ion-binding sites, which physiologically bind
Ca2+ (36), share some coordinating residues in common with the MIDAS, and are known as
the LIMBS (ligand-induced metal ion-binding site) and ADMIDAS (adjacent to metal ion-
dependent adhesion site) (31,32) (Figure 4b and Figure 7b).
Structures of αVβ3 (32) and αIIbβ3 (36) show that peptides containing ligand-mimetic Arg-
Gly-Asp (RGD) sequences bind across the α-β subunit interface in the head (Figure 7c,d). The
Asp carboxyl group directly coordinates the β I domain MIDAS Mg2+ ion, whereas the Arg
side chain hydrogen binds to Asp residues in the αV or α IIb β-propeller domains (Figure 7d).
The binding site for macromolecular ligands is larger. Residues shown by mutagenesis to be
important for binding to fibrinogen (smaller spheres, Figure 7c) decorate the cap subdomain
of the β-propeller (in Figure 7c, green), the remainder of the β-propeller (magenta), and the
β I domain (cyan). The cap subdomain is formed by several insertions that are unusually long
in α IIb in β-propeller domain β-sheets (blades) 2 and 3. The ligand-binding site in the β-
propeller is formed largely by β-sheets 2 and 3, which lie opposite the ligand-binding MIDAS
and SDL of the β I domain.
The α and β Subunit Legs
In the α subunit, the region C-terminal to the β-propeller comprises the leg of the α subunit
and contains three β-sandwich domains. The upper leg contains the thigh domain and the lower
leg consists of the calf-1 and calf-2 domains. A small Ca2+-binding loop located between the
thigh and calf-1 domains represents the α subunit genu, the key pivot point for switchblade
extension in the α subunit (Figure 6 and Figure 7a).
The topology of the β subunit is more complex. The β I domain is inserted in the hybrid domain,
which forms the upper portion of the upper β leg (Figure 6a,b). In turn, the hybrid domain is
inserted in the plexin/semaphorin/integrin (PSI) domain (Figure 6a,b). The second segment of
the PSI domain is very short but can be assigned as part of the PSI domain because it contains
β3-Cys435, which is involved in a long-range disulfide bond to β3-Cys11 in the first segment
of the PSI domain, and this disulfide is structurally conserved in other PSI domains (36,40,
41).
The remainder of the β leg is built from four integrin epidermal growth factor-like (I-EGF)
domains and a β tail domain. I-EGF domains 1 and 2 were not resolved in the αVβ3 crystal
structure. However, an NMR structure of β2 I-EGF3 and studies on I-EGF2 and I-EGF3
established an extended orientation between these domains. Furthermore, a structure of the
β2 PSI, hybrid, and I-EGF1 domains has been solved (41). Superposition of these structures
on the bent αVβ3 structure establishes that the bend in the β leg, or knee, is located between
I-EGF domains 1 and 2, as suggested earlier (42). The PSI and I-EGF1 domains are located
side by side (Figure 6b). The bends in the α leg at the genu and in the β leg between I-EGF1
and I-EGF2 are located close to one another and in a geometry appropriate so that extension
can occur by pivoting of the headpiece about an axis through the α and β subunit knees (Figure
6c,d), as shown by EM studies (33,43). Consistent with these findings, many antibodies that
either activate or report activation in cell surface integrins map to the PSI and β I-EGF domains
(44–47). Furthermore, αL antibodies that report extension map to the inner face of the thigh
domain and require genu Ca2+-coordinating residues for binding and thereby provide evidence
that integrin extension occurs by a rearrangement at the thigh/genu interface (48).
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Conformational Regulation of Integrin Extracellular Domains
Conformational Activation of β I Domains
In the bent conformation, the ligand-binding site is not in an optimal orientation for binding
macromolecular ligands in the extracellular matrix or on the surface of other cells (Figure 6c,d).
However, integrins in the bent conformation can bind ligands, as clearly shown by soaking an
RGD ligand-mimetic peptide into preformed crystals (32). Ligand binding induced movements
in the β1-α1 and β6-α7 loops (liganded-closed conformation, Figure 4b). However, downward
displacement of the α7-helix was not seen (32).
When an αIIbβ3 headpiece was first mixed with ligand-mimetic drugs, and then crystals were
allowed to form, a different conformation, termed liganded-open, was obtained (36). In the
high-affinity, liganded-open β I domain, compared with the low-affinity, unliganded-closed
β I domain, marked movements occur of the β1-α1 and β6-α7 loops and of the α1- and α7-
helices (Figure 4b). Coordination of the Met335 backbone carbonyl in the β6-α7 loop to the
ADMIDAS Ca2+ ion in the low-affinity, unliganded conformation is broken in the high-
affinity, liganded conformation. This enables the ADMIDAS metal and residues in the β1-α1
loop that coordinate to both the ADMIDAS and MIDAS metals to shift markedly, remodel the
ligand-binding site, and increase affinity for ligand. These movements are tightly coupled, so
that reshaping to the high-affinity, ligand-binding site is allosterically linked to downward
movement of the α7-helix. This linkage is critical for propagation of conformational signals
from the ligand-binding pocket to the other integrin domains and vice versa (Figure 4b). When
the RGD-mimetic is soaked into preformed crystals (liganded-closed, Figure 4b), the β1-α1
loop moves almost as much but does not have as optimal an interaction with ligand as in the
liganded-open structure, and the remaining movements are frustrated by crystal lattice contacts.
Effects of Mn2+ and Ca2+
Compared with results in the physiologic divalent cations Mg2+ and Ca2+, which are present
at ∼1 mM in body fluids, addition of Mn2+ or removal of Ca2+ increases ligand-binding affinity
and adhesiveness of almost all integrins. Recent studies show that binding of metal ions to the
LIMBS and ADMIDAS sites can explain these effects (49,50). Mutational studies show that
the LIMBS functions as a positive regulatory site, and the ADMIDAS functions as a negative
regulatory site (49–51). Additionally, in α5β1 and αLβ2 integrins, the ADMIDAS functions
in transmission of allostery between the β I domain and other domains (50,51). For most
integrins, Ca2+ has both positive and negative regulatory effects. High concentrations of
Ca2+ inhibit adhesion, whereas low concentrations of Ca2+ synergize with suboptimal Mg2+
concentrations to support adhesion. The LIMBS mediates the synergistic effects of low Ca2+
concentrations (49,50), whereas the ADMIDAS mediates the negative regulatory effects of
higher Ca2+ concentrations, which are competed by Mn2+ (49).
Communication Between the α I and β I Domains
Conformational regulation of integrins containing an α I domain requires the additional step
of transmission of allostery from the β I domain to the α I domain (Figure 6d). An invariant
Glu residue, E-310 in αL, in the linker between the C-terminal α7-helix of the α I domain and
β-sheet 3 of the β-propeller domain is required for α I domain activation (52,53). It has been
proposed that this invariant Glu residue acts as an intrinsic ligand and binds to the β I MIDAS
when it is activated and that it exerts a downward pull on the α7-helix and activates the α I
domain (53,54) (Figure 8a). Yang et al. (54) provided direct evidence for an activating
interaction between αL residue 310 and the β2 MIDAS. Individual mutation of the αL linker
residue Glu-310 or β2 MIDAS residue Ala-210 to cysteine abolishes I domain activation,
whereas the double mutation of αL-E310C and β2-A210C results in formation of a disulfide
bond that constitutively activates ligand binding (54) (Figure 8b).
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α/β I Domain Allosteric Antagonists
Small molecule integrin antagonists have yielded further insight into the mechanisms for α I-
β I communication. A class of αLβ2 and αMβ2 small molecule antagonists perturbs the
interface between the α I domain and the β I domain (55–57). These antagonists do not inhibit
binding of isolated wild-type or mutant intermediate- or high-affinity α I domains to ICAM-1
(56). Furthermore, these inhibitors bind to αLβ2 even when the α I domain is deleted, but do
not bind when the β I domain MIDAS is mutated (56). Some but not all compounds of the
series exhibit α subunit selectivity, suggesting that a portion of the α subunit nearby the β I
domain, likely the β-propeller domain or its linkers to the α I domain, is involved in binding.
Therefore, these inhibitors have been designated as α/β I domain allosteric antagonists.
These antagonists apparently bind to the MIDAS of the β2 I domain, competitively inhibit
binding of the intrinsic ligand in the α I domain linker, and thus leave the α I domain in its
default low-energy, inactive, closed conformation. At the same time, the α/β I allosteric
antagonists mimic intrinsic ligand binding and thereby stabilize the β I domain in its active
configuration, as shown by induction of activation epitopes in the β2 I domain, as well as the
αL and β2 legs (56). The antagonists induce integrin extension as shown in EM studies (43).
In in vitro shear flow assays and in vivo, the antagonists enhance rolling of leukocytes and
inhibit firm adhesion (57). These results on ICAM-1 substrates suggest that the postulated αL
Glu-310-β2 MIDAS interaction is not required for rolling adhesion, in agreement with the
ability of isolated, wild-type αL I domains to support rolling adhesion (58,59), but is required
for firm adhesion. LFA-1 containing an αL Glu-310 → Ala mutation shows lowered expression
of activation epitopes in the β2 I domain and leg, demonstrating cooperativity between the
postulated αL Glu-310-β2 MIDAS interaction and conformational rearrangements elsewhere
in the LFA-1 molecule. This mutant is also deficient in supporting rolling interactions on
ICAM-1 substrates. However, treatment of αL Glu-310 LFA-1 mutants with α/β I allosteric
antagonists induces epitope exposure and renders them competent to support rolling, consistent
with the hypothesis that these antagonists bind to the same site to which αL Glu-310 binds
(59).
Hybrid Domain Swing-Out and Integrin Extension
The orientation between the β I and hybrid domains appears to be the critical translator
converting global conformational change into local intradomain conformational changes that
regulate integrin affinity for ligand (see Figure 4b and Figure 6c,d ). As a consequence of the
topology of insertion of the β I domain in the hybrid domain, the piston-like displacement of
the α7-helix in the high-affinity, liganded structure results in complete remodeling of the
interface between these domains, leading to the swing-out of the hybrid domain (36) (Figure
4b). Actually, the α7-helix functions more like a connecting rod than a piston because as it
moves downward, its angle changes (Figure 4b), like a connecting rod between a piston and a
crankshaft. This forces rotation about a crankshaft bearing (circled in Figure 4b) between the
last β-strand of the hybrid domain and the first β-strand of the β I domain. Note the structural
design of this machine: Hydrogen bonds in α-helices are all internal, allowing them to move
independently of other structural units, whereas the three other connecting units between the
β I and hybrid domains are β-strands, which are fixed in position within β-sheets by hydrogen
bonds. Therefore, there is little compliance in the central β I domain β-sheet or the two hybrid
domain β-sheets. This enables the rearrangement of the loops around the β I domain MIDAS
to be transmitted as a 60° swing of the hybrid domain away from the α subunit and a 70 Å
movement of the rigidly connected PSI domain, i.e., a 70 Å separation of the integrin knees
(36,41) (Figure 4b).
Three major integrin conformations have been resolved by crystal and EM studies (Figure
6c,d). The bent conformation contains a closed headpiece (31). The hybrid domain is highly
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buried in the interfaces that stabilize the bent structure, and therefore its swing-out destabilizes
the bent conformation (33). By contrast, the extended integrin conformation is compatible with
both closed and open headpiece conformations (33,43) (Figure 6c,d and Figure 9a,b). The
influence on equilibration between these states has been studied of a flexible, C-terminal clasp
fused to the C termini of the α and β subunit ectodomains, which mimics association between
the α and β subunit transmembrane domains (33,43). Whereas clasped αVβ3 or αXβ2 particles
are predominantly in the bent conformation (see panel 1 of both Figure 9a and b), unclasped
particles are predominantly extended. For αVβ3 and αXβ2, about half of unclasped, extended
particles have the closed headpiece (see panel 2 of both Figure 9a and b) and half have the
open headpiece (see panel 3 of both Figure 9a and b) (33,43). Therefore, once these integrins
extend, the energies of the closed and open headpiece conformations must be comparable.
However, the energetics for conformational transitions appear to vary among integrins, as
exemplified with αLβ2. Thus, clasped αLβ2 shows about equal proportions of bent and
extended particles, and unclasped αLβ2 particles adopt predominantly the closed headpiece,
with a smaller proportion of particles having the open headpiece (43).
A large number of studies are in agreement with the three integrin conformational states
described above and support the importance of hybrid domain swing-out in inducing high
affinity for ligand. EM studies of the α5β1 headpiece show that hybrid domain swing-out occurs
upon binding fibronectin fragments (34). Electron tomography of negatively stained, active,
detergent-soluble α IIbβ3 purified on an RGD peptide affinity column reveals an extended
conformation with >90% of particles showing an open headpiece structure that matches
perfectly (60) the open, liganded α IIbβ3 headpiece crystal structure (36). In addition to
structural investigations (33,34,36,43,60,61), integrin hybrid domain swing-out is supported
by a range of other studies. Stabilizing the open headpiece by mutationally introducing an N-
glycosylation site into the hybrid-β I domain interface increases ligand-binding affinity (62,
63). As shown by epitope mapping and EM, an allosteric β1 antibody that inhibits ligand
binding restricts the swing-out of the hybrid domain (63). The functional properties of an
inhibitory β2 mAb suggest it also inhibits by blocking signal transmission at the β I-hybrid
domain interface (64). Moreover, activation-dependent mAbs map to the inner face of the
hybrid domain, consistent with exposure of this face after swing-out (65,66), and specific
mutations of the β I domain α7-helix facilitate hybrid domain swing-out (65).
In contrast to the consensus in the above studies, an alternative deadbolt model (67) has
received little experimental support, as reviewed in more detail elsewhere (68). The presumed
deadbolt interface between β3 Val332 and Ser674 is extremely small, at 60 Å2 (67), and a
three-residue deletion of β3 residues 672–674 that removes this interface has no effect on ligand
binding to cell surface integrins αVβ3 and αIIbβ3 ( J. Zhu, B. Luo & T.A. Springer, unpublished
observation). One negative-stain EM study found that ligand binding to αVβ3 did not induce
extension (69); however, much greater particle aggregation was present than in other studies
and must have complicated the analysis.
The use of functionally well-characterized antibodies in EM experiments has provided
definitive evidence that integrin extension occurs on intact cells in response to physiologic
stimuli and is sufficient to activate integrin adhesiveness (43). Extensive, physiologically
relevant studies of β2 integrins on intact cells have shown that CBR LFA-1/2 mAb induce the
high-affinity state and that, depending on the experimental system, KIM127 mAb can either
stabilize or report the high-affinity state (35,45,54,57,70–76). The binding sites for KIM127
and CBR LFA-1/2 antibodies have been mapped to the I-EGF2 and I-EGF3 domains,
respectively (45,77). Although clasped αXβ2 was >95% in the bent conformation, binding of
CBR LFA-1/2 Fab induced complete conversion to the extended conformation (43) (Figure
9c, panels 1–3). Furthermore, KIM127 Fab bound only when extension was induced by another
agent such as CBR LFA-1/2 Fab or an α/β allosteric antagonist. In combination with the
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following cited functional studies, the EM study (43) established that (a) extension is sufficient
to activate ligand-binding competence by β2 integrins (35,45,54,72–76,78), (b) ligand-bound
β2 integrins on cell surfaces are extended (70,71), (c) binding to soluble ligand induces
extension (57), and (d ) extracellular activation of integrins by Mn2+ and inside-out activation
of integrins stimulated by protein kinase C or cytoplasmic domain mutations induce the
extended conformation in the absence of ligand binding (35,45,75).
When viewed in combination, the crystal and EM studies demonstrate two structurally linked
mechanisms for activating integrin adhesiveness. First, extension moves the ligand-binding
head 100 Å to 200 Å further away from the cell surface and orients it optimally for adhesion
to another cell or to the extracellular matrix. Second, extension enables hybrid domain swing-
out, which induces increased affinity for ligand.
The Compliant Integrin Legs
The design of the connecting rod and crankshaft bearing between the β I and hybrid domains
and the rigidity of the hybrid domain/PSI domain unit amplify reshaping of the ligand-binding
site into a 70 Å separation at the integrin knees. Such a large movement appears to be important
for transmission of conformational change to the transmembrane and cytoplasmic domains
because the β leg in particular is highly compliant, i.e., flexible. Below, we discuss the role of
integrin α and β subunit transmembrane domain separation in activation. Transmembrane
domain separation, extension, and hybrid domain swing-out are linked; however, this linkage
is not tight because of the flexibility of the lower β leg. When extended αVβ3 or αXβ2 particles
are imaged and class averaged, the domains in the lower β leg tend to disappear because they
appear in different orientations and are averaged out (33,43) (panels 2 and 3 in both Figure 9a
and b). Fab binding results in better resolution of the lower β leg, both in clasped (Figure 9c,
panels 1–3) and unclasped preparations (Figure 9c, panel 4). Both parallel and crossed
orientations of the α and β legs are seen (Figure 9c, panels 1 and 2, respectively), and the β leg
is clearly flexible above the Fab-binding sites in I-EGF domains 2 and 3, i.e., at the knee
between I-EGF1 and I-EGF2, and appears to be flexible at other locations as well. This
flexibility is symbolized with the dashed β legs in Figure 6c,d. In αVβ3 the α leg snaps into a
preferred orientation when it is extended (33) (Figure 9a, panels 2 and 3). In αXβ2 the extended
α leg is flexible at the genu (43) (Figure 9b,c).
Conformational Change of the Integrin Cytoplasmic and Transmembrane
Domains
In the bent αVβ3 crystal structure, the α and β subunit ectodomain C termini are a few angstroms
apart (31), consistent with association of the α and β subunit transmembrane domains.
Ectodomain constructs with the C termini clasped have lower affinity for ligand than unclasped
constructs (79). Many studies show that deletions or mutations in the α and β subunit
transmembrane and cytoplasmic domains, which are expected to destabilize α/β association,
activate integrins (80–83). Furthermore, replacement of the αL and β2 cytoplasmic domains
with ACID/BASE peptides that form a heterodimeric α-helical coiled-coil stabilizes αLβ2 in
an inactive state, whereas replacement with similar peptides that do not heterodimerize causes
constitutive activation of αLβ2 (84). Fluorescent proteins were fused to the αL and β2
cytoplasmic domains for fluorescent resonance energy transfer (FRET) studies. These studies
on live cells show that in the resting state the integrin α and β subunit cytoplasmic domains
are close to one another (35). However, they undergo significant spatial separation upon inside-
out activation induced by stimulation of protein kinase C, stimulation by a chemoattractant of
a G protein-coupled receptor, or transfection with the talin head domain, which binds the
integrin β cytoplasmic domain. Furthermore, extracellular addition of Mn2+ and soluble
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ICAM-1, which induces integrin extension as shown by exposure of the KIM127 epitope, also
induces α and β subunit cytoplasmic domain separation (35).
NMR studies of the integrin cytoplasmic tails suggest that their association is weak, with
significant differences between published structures of associated cytoplasmic domains (85,
86) or with undetectable association between α and β subunit cytoplasmic domains (87,88).
These studies imply that the cytoplasmic interaction is modest and/or transient and that other
domains are required for stable α and β association. Binding of intracellular proteins such as
RAPL (89) and the talin head domain (90–92) to the integrin cytoplasmic tails activates
integrins for ligand binding, presumably by disrupting α and β association. Other proteins also
bind to the cytoplasmic tails, including filamin, which competes with talin for binding to the
β tail and modulates cell migration (93), and ICAP-1, which binds to the same motif as talin
and has a related fold (94). The structural basis for talin and filamin binding to the integrin β
cytoplasmic domain has been demonstrated by NMR and crystal studies (91,95,96).
Mutational studies have defined interfaces on the integrin α and β subunit transmembrane
domains that, when substituted, result in activation (97–100). Furthermore, disulfide scanning
of the exofacial portions of the transmembrane domains revealed a specific α-helical interface
between the α and β transmembrane domains in the resting state (97). Disulfide scanning also
revealed that after activation from inside the cell, the α and β subunits moved apart in the
membrane instead of rearranging into a distinct α/β interface.
A Model for Bidirectional Signal Transmission by Integrins Across the
Plasma Membrane
Based on the preponderance of the results described above, the following model is evident.
Integrins are in equilibrium between different conformational states (Figure 6c,d). The bent
conformation is stabilized by interfaces between the headpiece and the lower legs, between the
lower α and β legs (33), and between the α and β transmembrane and cytoplasmic domains.
However, none of these interfaces is tight, and small perturbations can readily shift the
equilibrium toward extension and separation. Perturbation of the cytoplasmic domains by
mutation or by binding of the talin head domain or other effector proteins induces separation
of the cytoplasmic and transmembrane domains. This in turn results in separation of the α and
β lower legs. Lower leg separation destabilizes the interface between the lower legs and the
headpiece and results in integrin extension. Transmembrane domain separation would favor
the open over the closed headpiece because the upper α and β legs are 70 Å further apart in the
open than the closed headpiece. However, because the lower β leg is highly flexible,
transmembrane domain and lower leg separation and extension would not be sufficient to
enforce hybrid domain swing-out [compare panel 2 of Figure 6c or d (with dashed β leg) with
panel 3 of Figure 6c or d (with solid β leg)]. EM studies and results with activation-dependent
antibodies demonstrate that extension is sufficient to induce integrin adhesiveness and to enable
a substantial proportion of integrin molecules to equilibrate to the high-affinity, open headpiece
conformation. The set point for the equilibria between bent and extended conformations and
between extended open headpiece and extended closed headpiece conformations is integrin
dependent (43) and may help explain differences between integrins in their susceptibility to
activation (101).
The mechanochemical design of integrins favors extension and hybrid domain swing-out when
integrins function in adhesion. The distance in the β subunit between the ligand-binding site
and the I-EGF1 domain is 20 Å further (Δx) in the open than in the closed headpiece
conformation (see Figure 4b). Therefore, in cell migration or as a consequence of cytoskeleton
contraction, when tensile force (F) is exerted on a ligand-bound integrin and resisted by
cytoskeletal proteins bound to the β subunit cytoplasmic domain, the open headpiece
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conformation will be stabilized relative to the closed headpiece by approximately FΔx.
Notably, the extended conformation would similarly be favored over the bent conformation
and has a substantially greater Δx. Thus, a mechanochemical switch favors the high-affinity
state when tensile force is applied to integrins, and this is expected to be of great importance
for force resistance and mechanotransduction by integrins during cell adhesion and migration
(102). This mechanochemical design stabilizes the high-affinity state when tensile force is
applied to selectins and integrin α I domains as well, and the importance of how force is linked
to allostery has been experimentally demonstrated for α I domains (103).
Conformational change can also be transmitted from the integrin ligand-binding site to the
cytoplasm, as demonstrated with FRET (35). Which integrin conformation first binds ligand
is unknown and may depend on (a) the rate of equilibration between different conformational
states, (b) the population of the different states, and (c) the binding kinetics and affinities of
the different states. However, the preponderance of EM and crystal structure studies
demonstrates that once ligand is bound, it stabilizes the extended conformation with the open
headpiece. Swing-out of the hybrid domain would favor, but seems unlikely to enforce,
transmembrane domain separation because of the flexibility of the lower β leg (compare
integrins with dashed and solid β legs in panel 3 of Figure 6c or d ). In agreement, a disulfide
bond between the exofacial portions of the α and β subunit transmembrane domains does not
prevent extracellular agents such as Mn2+ and antibodies from activating ligand binding,
although it does prevent intracellular signals from activating ligand binding (97). It seems likely
that the stability of α and β subunit transmembrane and cytoplasmic domain association is low,
and that in the absence of close association between the α and β ectodomain C-terminal
segments, the transmembrane and cytoplasmic domains spontaneously dissociate and thereby
transmit signals into the cell.
Role and Regulation of Integrin Lateral Association
As discussed above, conformational mechanisms for regulating integrin affinity have become
relatively well established. However, the role and regulation of integrin lateral redistribution
on the cell surface, often referred to as clustering, has remained unclear and controversial
(104). Several early studies suggested a dominant and proactive role for integrin redistribution
in the initiation or priming of cells for efficient ligand binding (105). In practice, such valency
regulation (104) has usually been inferred when activators promote cell adhesion without
promoting detectable soluble ligand binding. However, this appears to reflect a lack of
sensitivity of assays to intermediate levels of affinity, rather than a lack of affinity regulation.
Recent improvements in soluble ligand-binding assays and studies with Fabs specific for the
high-affinity conformation have clearly demonstrated rapid and transient integrin affinity
regulation in response to chemokines (14,106–108). Furthermore, sensitive assays often
demonstrate that physiological stimuli normally induce markedly less soluble ligand binding
than Mn2+ (109), which has been commonly employed as a positive control for affinity
regulation.
The idea of clustering as a mode of priming implies proactive and directed mechanisms for
lateral redistribution (110). Vesicular trafficking (111,112) and Rap1- and RAPL-driven
polarization of integrins to the lamellapodium (89,113) represent important active modes of
integrin reorganization that take place during cell migration. However, mechanistic support
for active reorganization of integrins during the initial stages of priming remains tenuous. On
the basis of the observation that peptides containing integrin α and β subunit transmembrane
domains form homodimers and homotrimers in detergent, investigators have proposed that
homomeric association between the transmembrane domains can induce integrin clustering
(114). However, several subsequent studies in intact cells have shown that homomeric α- α or
β-β association does not occur as a consequence of integrin priming and dissociation of αβ
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transmembrane domain heterodimers (75,98). Other studies have implied a role for cholesterol-
rich lipid rafts in driving integrin clustering, but this has remained controversial (104).
Many of the ideas on activation-induced integrin clustering have been replaced by an emerging
model of multivalent ligand-dependent, mass-action-driven integrin redistribution that is
modulated by the cytoskeleton (104). On resting cells β2 integrin mobility is confined by
cytoskeletal interactions with the cytoplasmic tail (115). Cell activation by PMA or chemokine
increases LFA-1 diffusion on the membrane (106,116). Moreover, artificially increasing
LFA-1 diffusiveness by actin cytoskeleton disruption enhances both mobility and adhesion
(116). However, redistribution or clustering of integrins was not induced directly by treatments
that increased membrane mobility alone, and redistribution was, instead, dependent on the
presence of multivalent ligand substrates, suggesting a ligand- and mass-action-driven
redistribution model that functions in adhesion strengthening rather than in priming (75,117).
Complexity is added to this model by findings that LFA-1 (118,119) and other integrins
(120) become confined upon ligand binding or stabilization of the open integrin conformation
and that diffusion rates may depend on affinity states (121).
Integrin Outside-In Signaling
Binding of extracellular ligands by integrins results in signal transduction across the plasma
membrane that regulates cell shape, migration, growth, and survival, a process termed outside-
in signaling. Details of the many signaling pathways emanating from integrins are beyond the
scope of this review, and readers are referred to several recent and extensive reviews (122–
125). Investigators widely believe that lateral association (i.e., clustering) of integrin
heterodimers, which occurs as a consequence of multivalent ligand binding (75,117), plays a
major role in outside-in signaling (see review in Reference 122). However, ligand binding can
also directly lead to and stabilize separation of integrin cytoplasmic domains (35). To
characterize the role of integrin conformational change (e.g., separation of the transmembrane
and cytoplasmic domain interfaces) in outside-in signaling, a mutant with an intersubunit
disulfide bond between the α and β transmembrane domains (97) was studied. The α IIbβ3
mutant retains Mn2+-stimulated ligand binding as described above and mediates adhesion to
fibrinogen substrates. However, this mutant exhibits a profound defect in adhesion-induced
outside-in signaling as measured by cell spreading, actin stress fiber, focal adhesion formation,
and focal adhesion kinase activation ( J. Zhu, C. Carman, M. Kim, M. Shimaoka, T.A. Springer
& B. Luo, unpublished observations). These defects in outside-in signaling were rescued by
reduction of the intersubunit disulfide bond. Thus, separation of transmembrane domains is an
important component of integrin outside-in signal transduction. The role of clustering might
then be to facilitate interactions among different integrin-bound and focal adhesion-associated
kinases to promote transphosphorylation/activation events in a fashion loosely analogous to
the well-characterized paradigm of receptor tyrosine kinase subunit-subunit transactivation.
Concluding Remarks
Recent structural, biochemical, and biophysical studies have greatly advanced our
understanding of the mechanisms of integrin bidirectional signaling across the plasma
membrane. Indeed, perhaps more is known about how integrins transmit signals across the
membrane than for any other receptors with two transmembrane domains, including receptor
kinases. Accumulating evidence demonstrates that conformational affinity regulation plays a
dominant role in integrin priming (inside-out signaling), whereas lateral redistribution
(clustering) functions in adhesion strengthening, and both integrin conformational change and
clustering are required for outside-in signaling. The many different conformational states of
integrins are in dynamic equilibrium. Intracellular signals or ligand binding act by shifting the
equilibrium, not by locking integrins in one specific state. Furthermore, inside-out signals
activate only a subset of integrin molecules on the cell surface, and these may have a localized
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cell surface distribution. Much more remains to be learned about integrin structure, dynamics,
and linkage to the cytoskeleton and both downstream and upstream effectors.
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Glossary
MIDAS  
metal ion-dependent adhesion site
ADMIDAS  
adjacent to metal ion-dependent adhesion site
I-EGF domain 
integrin epidermal growth factor-like domain
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The 24 integrin heterodimers. The α subunits with α I domains are asterisked. Integrin
heterodimers on immune cells are shown with red lines.
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A mutant, high-affinity αL I domain (gold β-sheet and coil and green α-helices) in complex
with domain 1 of ICAM-3 (cyan). The Mg2+ is shown as a gray sphere. The side chain of the
key integrin-binding residue, Glu37 of ICAM-3, is shown. The mutationally introduced
K287C/K294C disulfide bond that stabilizes the open conformation is shown in pink. ICAM-3
domain 2 is omitted for clarity. [From Protein Data Bank (PDB) ID code 1T0P (7).]
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Structural rearrangement of the αM I domain MIDAS. (a) Structure of the closed αM I domain
MIDAS. (b) Structure of the open α I domain MIDAS. Glu-314 from a neighboring αM I
domain coordinates with the MIDAS magnesium. Purple and green spheres are Mn2+ and
Mg2+ ions, respectively, and red spheres are coordinating water-molecule oxygens. [From PDB
ID codes 1JLM and 1IDO (4,8).]
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Conformational change and transmission of allostery by α and β I domains. (a) The α I domain.
Nonmoving segments of the backbone are shown as a gray worm. The moving segments of
the backbone and the MIDAS metal ions are closed (gold ) and open (cyan). The direction of
movement is indicated with arrows. [From PDB ID codes 1JLM and 1IDO (4,8).] (b) The β I
domain and its linkage to the hybrid and plexin/semaphorin/integrin (PSI) domain. Nonmoving
segments of the β I backbone are shown as a gray worm. Moving segments and metal ions are
color coded as shown. Directions of α1- and α7-helix movements are shown with arrows. [PDB
ID codes are 1U8C, 1L5G, and 1TXV (32,36,40).]
Luo et al. Page 24














ICAM structure and integrin binding. (a) Schematic of ICAM-1, -2, -3, and -5. The domains
are color coded, and integrin-binding sites are shown. (b) Structural model of ICAM-1
oligomers bound to αL I domain. The model was constructed from the structure of ICAM-1
D1-D2 in complex with αL I domain (PDB ID code 1MQ8) and from the structure of ICAM-1
D3-D5 (PDB ID code 1P53) (6,24). ICAM-1 is cyan, with the first carbohydrate residue at
each site in yellow; the αL I domain is purple.
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Integrin architecture. (a) Organization of domains within the primary structures. Some α
subunits contain an I domain inserted in the position denoted by the dashed lines. Cysteines
and disulfides are shown as lines below the stick figures. (b) Schematic of the course of the
α and β subunit polypeptide chains through domains from the N to C termini. (c-d )
Rearrangement of domains during activation of integrins that lack (c) or contain (d ) an α I
domain. The β subunit lower legs are flexible and are therefore shown in what may be the
predominant (solid representation) and less predominant (dashed lines) orientations.
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Crystal structures of integrins αVβ3 and αIIbβ3. (a) The structure of αVβ3 in the bent
conformation. The αV and β3 subunits are colored in green and red, respectively. (b)
Superposition of liganded-open αIIbβ3 and unliganded-closed αVβ3 headpieces. The α and
β subunits are colored in green and yellow in αVβ3 and in purple and light blue in αIIbβ3.
Calcium and magnesium ions in αIIbβ3 only are gold and gray spheres, respectively. (c) The
drug tirofiban is shown bound to the αIIbβ3 head, and mapping is shown of fibrinogen binding-
sensitive mutations. The clinically approved antagonist tirofiban is shown with yellow carbons,
blue nitrogens, and red oxygens. The cap subdomain of the β-propeller is in green. Ca2+ and
Mg2+ ions are large gold and gray spheres, respectively. Cβ atoms of fibrinogen binding-
sensitive residues are shown as small spheres in the same color as the domains in which they
are present. Disulfide bonds are yellow cylinders. (d ) The binding of eptifibatide to αIIbβ3
interface is depicted. The fragment of eptifibatide that mimics RGD is shown as a stick model
with carbon, nitrogen, and oxygen colored yellow, blue, and red, respectively. The binding
pocket is shown with αIIb and β3 in purple and light blue, respectively. Hydrogen bonds are
shown as gray dashed lines. Ca2+ and Mg2+ are gold and gray spheres, respectively. The
coordinations to the metal ions are shown as green dashed lines. [Structure PDB ID codes are,
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for αVβ3, 1U8C (40); for αIIbβ3 bound to eptifibatide, 1TY6; and for αIIbβ3 bound to tirofiban,
1TY5 (36).]
Luo et al. Page 28














Communication between α I and β I domains. (a) It has been proposed that αL-Glu-310 acts
as an intrinsic ligand that binds to the β2 I domain MIDAS and, thus, axially displaces the αL
I domain α7-helix in the C-terminal direction, reshapes the β6-α7 loop, and activates the αL I
domain MIDAS. (b) Individual mutation of αL-Glu-310 or β2-Ala-210 to cysteine abolishes
I domain activation, whereas the double mutation of αL-E310C with β2-A210C forms a
disulfide bond that constitutively activates ligand binding (104).
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EM negative-stain class averages of integrins αVβ3 and αXβ2 in bent and extended
conformations (33,43). The EM images of the extended conformations only are colored
according to the scheme shown in d. (a) αVβ3 in bent ( panel 1), extended with closed headpiece
( panel 2), and extended with open headpiece ( panel 3) conformations. (b) αXβ2 in bent
( panel 1), extended with closed headpiece ( panel 2), and extended with open headpiece
( panel 3) conformations. (c) αXβ2 in complex with CBR LFA-1/2 Fab illustrates flexibility
of the β leg: panel 1, closed headpiece with parallel legs; panel 2, closed headpiece with crossed
legs; panels 3 and 4, open headpiece. Panels 1–3 are with clasped αXβ2, and panel 4 is with
unclasped αXβ2. In a-c, a schematic in the same orientation as the right-most panel is shown
to the right; the dashed lower β legs symbolize flexibility and averaging-out.
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